Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS (NCT07322003)
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Pridopidine in Participants With Amyotrophic Lateral Sclerosis
🩺 Plain-English Summary (8th-Grade Level)
The goal of this clinical trial is to learn if the drug pridopidine works to treat amyotrophic lateral sclerosis in adults. It will also help to learn about the safety of pridopidine. The main question it aims to answer is: Does pridopidine slow disease progression of ALS? Researchers will compare pridopidine to a placebo (a look-alike substance that contains no drug) to see if pridopidine works to treat ALS. Participants will: Take pridopidine or a placebo by mouth every day for 48 weeks. Afterwards, all participants will take pridopidine for another 48 weeks. Visit the clinic once every 1-3 months for checkups and tests
Who can join: Review the eligibility criteria below.
Location: Barrow Neurological Institute — Phoenix, Arizona
Age range: 18 Years to 80 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (56 Sites)
Showing the first 25 of 56 sites.
- Barrow Neurological Institute — Phoenix, Arizona
- California Pacific Medical Center — San Francisco, California
- University of Colorado CU Anschutz Neurology — Aurora, Colorado
- Mayo Clinic — Jacksonville, Florida
- University of South Florida — Tampa, Florida
- Emory University — Atlanta, Georgia
- Northwestern University — Chicago, Illinois
- University of Kansas — Fairway, Kansas
- Johns Hopkins University — Baltimore, Maryland
- Sean M. Healey & AMG Center for ALS — Boston, Massachusetts
- Washington University — St Louis, Missouri
- Somnos Clinical Research — Lincoln, Nebraska
- Eleanor and Lou Gehrig ALS Center at Columbia University — New York, New York
- Neuroscience Department at LKSM at Temple University — Philadelphia, Pennsylvania
- Texas Neurology — Dallas, Texas
- Baylor College of Medicine; McNair Medical Campus — Houston, Texas
- Swedish Medical Center — Seattle, Washington
- University of Washington — Seattle, Washington
- UZ Leuven — Leuven,
- Genge Partners — Montreal, Quebec
- University of Alberta — Edmonton,
- McMaster University Medical Centre — Hamilton,
- CHU Lille — Lille,
- Hôpitaux Universitaires de Marseille Timone — Marseille,
- Centre Hospitalier Universitaire de Nice — Nice,
📞 Contact the Study Coordinator
Phone: (857) 574-5755
Email: MedInfo@prilenia.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Amyotrophic Lateral Sclerosis
- Intravenous Immunoglobulin (IVIG) and Blood-Brain Barrier Disruption in Amyotrophic Lateral Sclerosis (ALS) — Toronto, Ontario
- Regulatory T Cells for Amyotrophic Lateral Sclerosis — New York, New York
- Rho Kinase Inhibitor in Amyotrophic Lateral Sclerosis (REAL) — Phoenix, Arizona
- TRIAL READY (Clinical Trial Readiness) — Miami, Florida
- Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis Treatment — Phoenix, Arizona
- Personalized Antisense Oligonucleotide for a Single Participant With CHCHD10 ALS — New York, New York
Explore by condition: All Amyotrophic Lateral Sclerosis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.